XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.
RSPH offers broader sector diversification with lower volatility, while XBI delivers higher short-term gains but with steeper drawdowns.
Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.
XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown.
Smart Beta ETF report for XBI
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Over six years, U.S. nominal GDP rose 63% while the 30-year Treasury fell 60%. Are investors positioned for a surge in stocks and yields?
XBI may have peaked after a 60% rally as tailwinds fade, equity supply hits cycle highs, and momentum rolls over. Click to read more about XBI's sell rating.
VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.
Smart Beta ETF report for XTN
Smart Beta ETF report for XRT
Smart Beta ETF report for XHB
Buy XBI? Get outlook for the SPDR S&P Biotech ETF—8%–14% return target, M&A tailwinds, key risks, and volatility factors.
State Street SPDR S&P Biotech ETF is hovering around a buy point after breaking out. The fund is one of the holdings in IBD Leaderboard.
This is the newest page. Registered accounts read further back.